Zinc Supplementation, Inflammation, and Gut Integrity Markers in HIV Infection: A Randomized Placebo-Controlled Trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

This study aimed to assess the effect of zinc supplementation on inflammatory and gut integrity markers and on zinc levels among HIV patients with zinc deficiency.

Why It Was Studied

Zinc has major immunomodulatory effects.

At baseline and at week 24, the researchers measured plasma levels of zinc and markers of inflammation and gut barrier integrity.

Who Took Part

According to the abstract, 95 participants were involved.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

At baseline and at week 24, the researchers measured plasma levels of zinc and markers of inflammation and gut barrier integrity.

The subject headings attached to it are HIV Infections, Zinc, Dietary Supplements, Biomarkers, Inflammation, Lipopolysaccharide Receptors and Gluconates.

The authors tagged it with the keywords gut integrity, metabolic markers and monocyte activation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 95 participants.

The publication is from 2025 (Nutrients), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.